Mangoceuticals, Inc. Common Stock (MGRX) — Net Asset Quality Index
Mangoceuticals, Inc. Common Stock (MGRX) has a Net Asset Quality Index of 88.4% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $14.17 Million minus total liabilities of $1.65 Million yields net assets of $12.52 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of Mangoceuticals, Inc. Common Stock for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Mangoceuticals, Inc. Common Stock Net Asset Quality Index Over Time (2021–2025)
This chart shows how Mangoceuticals, Inc. Common Stock's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the index stands at 88.4%, representing net assets of $12.52 Million against total assets of $14.17 Million USD. For live market cap and overall valuation, see Mangoceuticals, Inc. Common Stock market capitalisation.
Annual Net Asset Quality Index for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for Mangoceuticals, Inc. Common Stock from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Mangoceuticals, Inc. Common Stock strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.5% | $15.20 Million | $16.09 Million | $890.57K | ▲ +3.7 pp |
| 2024 | 90.7% | $13.95 Million | $15.37 Million | $1.43 Million | ▲ +17.0 pp |
| 2023 | 73.7% | $774.75K | $1.05 Million | $276.04K | ▲ +12.5 pp |
| 2022 | 61.2% | $614.03K | $1.00 Million | $389.26K | ▲ +135.3 pp |
| 2021 | -74.1% | $-16.72K | $22.55K | $39.27K | — |